Ganymede Bio, The Cloud Provider Purpose-Built For The Life Sciences And Manufacturing Industries, Raises $12.75 Million In Series A Funding

Dec 20, 2022•over 2 years ago

Amount Raised

$12.8 Million

Round Type

series a

Palo AltoCyber SecurityInformation Technology

Investors

Caffeinated Capital

Description

Ganymede Bio, the cloud infrastructure provider purpose-built for the life sciences and manufacturing industries, today announced a $12.75 million Series A funding round, led by Caffeinated Capital. This follows a $2.9 million seed round completed earlier this year, bringing the total to over $15.6 million. Founded in 2022, the company has exceeded $1 million in revenue commitments, with clients ranging from early-stage biotechs to large, established biopharmaceutical companies.

Company Information

Company

Ganymede

Location

Palo Alto, California, United States

About

Ganymede is the cloud infrastructure provider purpose-built for the life sciences and manufacturing industries. Its Lab-as-Code technology integrates physical lab instruments, apps, data pipelines, and third-party partners like CROs and CDMOs together in a single cloud data layer. Ganymede accelerates time to innovation by giving scientists the ability to automate the world around them using cloud-controlled data flows. Launch your lab of the future today by visiting us at www.ganymede.bio.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech